Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

Acalabrutinib-venetoclax hits mark for fit TN CLL patients
14 Jan 2025
bởiAudrey Abella
The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).
Acalabrutinib-venetoclax hits mark for fit TN CLL patients
14 Jan 2025
Alectinib trumps crizotinib for ALK+ NSCLC
13 Jan 2025
bởiAudrey Abella
In the 7-year update of the phase III ALESIA trial, alectinib outdoes crizotinib for Asian patients with treatment-naïve, advanced or metastatic ALK+ non-small-cell lung cancer (NSCLC).